This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 26 March 2024; doi:10.1038/s41569-024-00997-0 In this Review, Bozkurt provides an overview of the management of patients with heartfailure across the full range of left ventricular ejection fraction, derived from the recommendations in the latest US and European guidelines.
Heartfailure, a prevailing global health issue, imposes a substantial burden on both healthcare systems and patients worldwide. With an escalating prevalence of heartfailure, prolonged survival rates, and an aging demographic, an increasing number of individuals are progressing to more advanced phases of this incapacitating ailment.
FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heartfailure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP HeartFailure II Study Executive Steering Committee. “As
Nature Reviews Cardiology, Published online: 26 January 2024; doi:10.1038/s41569-023-00986-9 In this Review, Varga and colleagues provide an overview of the evidence on immune checkpoint inhibitor-induced heartfailure and cardiac dysfunction that is unrelated to myocarditis, and discuss how pharmacological targeting of immune checkpoints might be (..)
Introduction The aims of chronic heartfailure (HF) management are: to provide symptom relief to prevent hospitalisation for HF to improve survival. Optimal pharmacological and non-pharmacological management (including device treatment) have had an enormous beneficial impact on the clinical course of HF.
A research team in the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), found that hip fractures not only result in both physical and psychological injuries, but may also induce adverse cardiovascular events.
Secondary mitral regurgitation (SMR) is a complex and evolving challenge in the landscape of heartfailure (HF) management. 3 Should we continue with a conservative, stepwise approach, beginning with pharmacological management and delaying intervention until MR severity worsens?
At the Association of Cardiovascular Nursing & Allied Professions conference in June, Professor Tiny Jaarsma called for a pillar of self-care to be added to heartfailure (HF) care guidelines. 1 Taylor et al. 2 agree that HF care needs an additional pillar and suggest cardiac rehabilitation.
Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heartfailure (HF).
Introduction Heartfailure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. We aimed to determine the clinical characteristics which were associated with optimisation of HF pharmacological intervention in the clinic, conducting multivariate regression analysis.
Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heartfailure (HF). Introduction Management of heartfailure (HF) requires multidisciplinary, pharmacological and non-pharmacological strategies, one component of which is exercise training.
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heartfailure.
In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.
In the QUEST trial, QLQX reduced the combined risk of cardiovascular death or heartfailure hospitalization (hazard ratio 0.78, 95% confidence interval 0.68–0.90), Taken collectively, these observations support a conceptual framework for understanding the mechanism of action for QLQX in heartfailure.
Abstract Despite remarkable improvements in the management of heartfailure (HF), HF remains one of the most rapidly growing cardiovascular condition resulting in a substantial burden on healthcare systems worldwide. Therefore, non-pharmacological interventions targeting autonomic imbalance in HF have been evaluated.
More than roughly 10-and-a-half hours of sedentary behavior per day was significantly linked with future heartfailure (HF) and cardiovascular (CV) death, even among people meeting recommended levels of exercise.
Heartfailure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heartfailure (HF) spectrum. However, cost-effectiveness considerations should be made.
Background: Midodrine is occasionally used off-label to treat hypotension associated with advanced heartfailure. Objectives: We sought to evaluate the effect of midodrine upon the GDMT prescription pattern and clinical outcomes of patients with decompensated systolic heartfailure.
Background Currently, there is no head-to-head comparison of novel pharmacological treatments for heartfailure with reduced ejection fraction (HFrEF). Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.
Associations of colchicine-related plasma proteins, incident heartfailure (HF) and cardiac structure and function. HFpEF, heartfailure with preserved ejection fraction; HFrEF, heartfailure with reduced ejection fraction.
Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heartfailure.
This review summarizes the multiple roles of miRNAs in the prediction and treatment of heartfailure (HF), including the molecular mechanisms regulating cell apoptosis, myocardial fibrosis, cardiac hypertrophy and ventricular remodelling, and highlights the importance of miRNAs in the prognosis of HF.
Journal of the American Heart Association, Ahead of Print. BackgroundThe effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied.
The “Pharmacology Program” will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients. 24 is guided by prominent clinicians and leaders, and focuses on important fundamentals in managing and treating heart conditions.
BACKGROUND:Cardiac metabolic dysfunction is a hallmark of heartfailure (HF). Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics. Circulation, Ahead of Print. Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism.
The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.
Heartfailure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide. Heartfailure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide.
Patients undergoing anthracycline-based cancer treatments have an increased risk of heartfailure (HF) and adverse metabolic outcomes such as malnutrition and cachexia. Patients undergoing anthracycline-based cancer treatments have an increased risk of heartfailure (HF) and adverse metabolic outcomes such as malnutrition and cachexia.
Lisinopril is commonly prescribed to manage conditions such as hypertension and heartfailure. Lisinopril is commonly prescribed to manage conditions such as hypertension and heartfailure.
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heartfailure or obesity, irrespective of diabetic status.
Introduction The incidence of arrhythmia in heartfailure with non-reduced ejection fraction (HFnon-rEF) in patients who have a history of hospitalisation is unclear.
Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heartfailure, hypertension, and numerous cardiomyopathies. Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heartfailure, hypertension, and numerous cardiomyopathies.
Diastolic dysfunction (DD) in heartfailure (HF) is associated with increased myocardial cytosolic calcium, and calcium-efflux via the sodium-calcium-exchanger depends on the sodium gradient. Beta-3-adrenoceptor (β3-AR) agonists lower cytosolic sodium and have reversed organ congestion. NCT01876433.
Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heartfailure (AHF) and volume overload. Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heartfailure (AHF) and volume overload.
AF increases the risk of stroke, heartfailure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heartfailure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.
Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heartfailure and myocardial infarction. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heartfailure and myocardial infarction.
levosimendan treatment in the management of advanced heartfailure. levosimendan treatment in the management of advanced heartfailure. In the latest years several studies described the impact of repetitive/intermittent i.v In the latest years several studies described the impact of repetitive/intermittent i.v
This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose–linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heartfailure (HF) in China.
Abstract: To synthesize the available evidence regarding differences in the long-term safety and efficacy of intermittent, repeated, or continuous palliative inotropic therapy among patients with advanced heartfailure (HF).
ABSTRACT: Management of heartfailure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms. Management of heartfailure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content